New York, USA, July 06, 2022 (GLOBE NEWSWIRE) -- Prostate Cancer Diagnosis and Therapy Market Overview
According to a Comprehensive Research Report by Market Research Future (MRFR), "Prostate Cancer Diagnostics and Therapy Market Information by Type, Component, End-User, and Region - Forecast till 2030", the prostate cancer diagnosis and therapy market will accrue a 13.7% CAGR between 2022 and 2030. By the end of 2030, the prostate cancer diagnosis and therapy market should touch USD 10.1 billion.
Prostate Cancer Diagnosis and Therapy Market Synopsis
Prostate cancer is one of the most commonly occurring non-cutaneous cancers globally. Steady increase in the geriatric population, prevalence of a sedentary lifestyle in developed economies, and the surging cases of urological disorder augment the development of prostate cancer worldwide.
The last few years have seen notable innovations in androgen receptor targeting with respect to prostate cancer. Other than this, advancements have been made in radiopharmaceutical-based therapy as well as immunotherapy, however; their optimal deployment in clinic is quite unclear. Significant advancements in prostate cancer diagnosis and therapeutics, such as abiraterone acetate, enzalutamide, cabazitaxel, radium-233 and sipuleucel-T have been made in the past couple of years.
Get Free Sample PDF Brochure @ https://www.marketresearchfuture.com/sample_request/1580
|Market Size||USD 10.1 billion|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Component, Product and End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Market Drivers||Leading pharma to launch products for treatment|
|Diet that's full of high-fat foods and junk food and smoking and heavy alcohol usage.|
Prostate Cancer Diagnosis and Therapy Market Competitive Landscape:
The affluent firms in the prostate cancer diagnosis and therapy market include
- Dendreon Pharmaceuticals LLC (US)
- Astellas Pharma Inc. (Japan)
- Bayer AG (Germany)
- Ipsen Pharma (France)
- Abbvie Inc. (US)
- Johnson & Johnson Services Inc. (US)
- AstraZeneca (UK)
- Tolmar Pharmaceuticals Inc. (US)
- Sanofi (France)
- Ferring BV (Switzerland)
Prostate Cancer Diagnosis and Therapy Market USP Covered:
Since the COVID-19 outbreak is a relatively new pandemic, the information about how it is related to prostate cancer is quite scarce. However, medical professionals confirm that cancer patients are at high risk of becoming severely ill in light of their weakened immune system. Those patients currently receiving treatments like chemotherapy, radiation therapy and bone marrow transplants are extremely susceptible to SARS-CoV-2. Even if the patient is not undergoing treatment therapy need to be careful as they are entirely out of danger from the virus. In short, the outbreak of the novel coronavirus has led to a higher need for prostate cancer diagnosis and therapy, which could result in further market growth.
Many of the healthcare related meetings such as oncology have become virtualized, since the worldwide lockdown. There has been a surge in the number of video or phone conferences, with the aim to maintain social distancing and prevent the spread of COVID-19. A majority of the urologists are being helpful in this situation; by bring down the demand for personal protective equipment, ventilators, and more by reducing surgeries while not compromising on the health of those afflicted with prostate cancer. In the coming years, the market for prostate cancer diagnosis and therapy can also benefit from the emergence of new generic products as the patents of various existing products are about to expire.
Renowned vendors and research teams worldwide are investing in research and development of various therapeutic items to treat prostate cancer. In addition to this, artificial intelligence is fast emerging as a significant trend in the global market, with its increasing use in cancer prognosis and diagnosis, thanks to its unprecedented level of accuracy.
Significant costs in association with targeted therapies for treating prostate cancer slow down the uptake of these therapies worldwide. Lower awareness level with regard to technological innovations in the therapeutic area in emerging countries is also likely to hamper the growth of the prostate cancer diagnosis and therapeutics market.
Chemotherapy generally displays poor response levels in later-stage of prostate cancer, and therefore, it is used as palliation for those with the hormone-refractory disease. The majority of the oncologists make no use of systemic therapies in the early phase of prostate cancer owing to the negative perception of early systemic therapy.
Prostate Cancer Diagnosis and Therapy Market COVID 19 Analysis
The COVID-19 outbreak's significant impact has led to numerous severe repercussions on people's health status across the world. The aftermath is linked with the significant social and economic burden on people worldwide. While the major policymakers are implementing new frameworks and industries are adopting advanced models of expansion to maintain their relevance, people are facing a series of mental trauma.
Around the world, the rising cases have spurred mental, and economic issues, especially among the elderly. Additionally, the global populace has been dealing with challenges owing to loss of livelihoods and is opting for family care to address the repercussions. The focus is largely on the treatment of COVID-19 and the development of a vaccine, which steers attention away from other markets. These factors will most likely be unfavorable for the prostate cancer diagnostics and therapy market in the years to come.
Browse In-depth Market Research Report (78 Pages) on Prostate Cancer Diagnosis and Therapy: https://www.marketresearchfuture.com/reports/prostate-cancer-market-1580
Prostate Cancer Diagnosis and Therapy Market Segmentation
The market for Prostate Cancer Diagnosis and Therapy has been considered for type, product, component, and end user.
The primary types outlined in the market study are small cell carcinoma, prostatic adenocarcinoma, and more. The types of therapy are hormone therapy (luteinizing hormone-releasing hormone antagonists, antiandrogens and luteinizing hormone-releasing hormone analogs), chemotherapy (regional chemotherapy and systemic chemotherapy), biologic therapy, as well as targeted therapy.
The product-based key segments can be analyzers, consumables and reagents.
The main components studied in the report include therapy as well as diagnosis.
The key market end users as mentioned in the MRFR report are hospitals & clinics, specialty centers, and more. Despite the soaring number of ambulatory surgical centers that offer therapies for treating prostate cancer, hospitals and clinics still remain the most popular medium of health care. This has resulted in significant demand of prostate cancer therapeutics via hospital and clinics, which account for more than half of the market share.
Prostate Cancer Diagnosis and Therapy Market Regional Insights
The regional distribution of the Prostate Cancer Diagnosis and Therapy Market comprises Asia Pacific/APAC, the Americas, the Middle East & Africa/MEA as well as Europe.
Since the year 2018, Americas has remained the most lucrative market, as a result of the significant number of prostate cancer cases and the expansive geriatric population here. The well-developed healthcare infrastructure and the quick rate at which prostate cancer is treated in the early stages helps enhance the market size even further. The rich knowledge level with regard to prostate cancer diagnosis and therapy, particularly in the United States/US also facilitates market advancement in the region.
Share your Queries @ https://www.marketresearchfuture.com/enquiry/1580
As the second lead in the global market, Europe can continue thriving during the assessment period, with the immense growth in the elderly populace combined with the mounting awareness level with regard to cancer among people. The market growth in Europe is also the result of the several initiatives taken by the government with regard to prostate cancer.
There is a high possibility that the APAC market can obtain the fastest expansion rate in the forthcoming period, on account of the several health insurance plans and schemes and the improving financial conditions of the people. The consistent growth of the healthcare sector across China and India along with the alarming increase in obesity levels and the consequent rise in cases of prostate cancer are also presumed to be favorable for the APAC market in the long run.
Discover more research Reports on Healthcare Industry, by Market Research Future:
Brachytherapy Market Information by type (High dose-rate (HDR) brachytherapy, Low dose-rate (LDR) brachytherapy, Pulse Dose Rate (PDR) brachytherapy), by device (after loader and applicators) by application prostate cancer, cervical cancer, breast cancer, skin cancer, others)- Forecast till 2028
Intelligent Pills Market Information by Applications (Sleeping disorders, capsule endoscopy, Reflux Monitoring, Mobility Monitoring, Stress Management, and others), Prescription (prescription smart drugs and others) - Forecast to 2027
Cholesterol Management Devices Market Share, Growth And Trends Analysis Types (Monitors, Wrist Monitors, Small Portable Instruments, Meters, Wireless Systems), Application (Hypercholesterolemia, Hypocholesterolemia, Cholesterol Testing), End Users (Home Healthcare, Hospitals, And Clinics) - Forecast Till 2027
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Market Research Future (Part of Wantstats Research and Media Private Limited) 99 Hudson Street, 5Th Floor New York, NY 10013 United States of America +1 628 258 0071 (US) +44 2035 002 764 (UK) Email: email@example.com Website: https://www.marketresearchfuture.com
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.